Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib + Azacitidine in AML with HOX Overexpression
NCT03513484Phase 1Active, not recruiting
- Sponsor
- Northwestern University
- Start
- Nov 2018
- Primary completion
- Dec 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in acute myeloid leukemia (AML), sponsored by Northwestern University. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Nov 2018; status: active, not recruiting.
02
Drugs
nintedanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03513484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03513484.